TP53 and neoplasm: Despite the fact that all the cell lines can significantly increase MHC-I, MHC-II, and PD-L1 expression under IFNγ treatment, only the STOSE and MOE-PTEN/p53 are immunogenic, evident by the increased survival of tumor-bearing mice when the cells are administered as a cellular vaccine.